Vicarious Surgical Inc.

Good afternoon. Thank you for attending the Vicarious Surgical's 2025 Second Quarter Earnings Call. My name is Cameron, and I'll be your moderator for today. All lines will be muted during the presentation portion of the call with an opportunity for questions and answers at the end. If you would like to ask a question, please press star 1 on your telephone keypad, and I would now like to pass the conference over to your host, Rissa Bytes from the Gilbarn Group. You may proceed.

Good afternoon. Today, after market closed, Icarus Surgical released financial results for the three months ended June 30, 2025. A copy of the press release is available on the company website. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results, or performance are forward-looking statements. All forward-looking statements, including, without limitation, those relating to obtaining approval for the vicarious surgical system and timing for any such approval, the timing of future clinical trials and FDA submissions, cash burn expectations, or operating trends in future financial performance, expense management, market opportunity, and commercialization are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the risk factors set forth in our Securities and Exchange Commission filings, including our most recent Form 10-K and Form 10-Q. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, August 12, 2025. Vicarious Surgical disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. I will now hand the call over to Adam Fax, co-founder and president, to begin prepared remarks. Adam?

Thank you, Marissa. Good afternoon, everybody. It's been an incredible journey leading Vicarious Surgical since its founding. From our earliest days through product development and preclinical testing, I have been continually inspired by the dedication of our team and the strength of our mission. Today, I am proud of the foundation we have built And I'm even more excited about what lies ahead. With that in mind, I am pleased to welcome Stephen Fromm as our new Chief Executive Officer. Stephen brings a strong track record of leadership across the healthcare and medtech industries, and he joins us at a pivotal moment in our company's evolution. His experience and perspective will be invaluable as we continue progressing toward our long-term goals. As I step into the role of president, I look forward to partnering with Stephen and the rest of our leadership team to build on the momentum we have created. Together, we remain focused on developing our technology, advancing our clinical programs, and fulfilling our mission to transform surgical care through groundbreaking robotic innovation. Stephen will share more on this topic. but as we are also using the leadership transition to take a broader look at our development path, including both technical progress and program strategy. With that, I'd like to turn it over to Stephen to introduce himself and share an update on his approach.